These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 16465702)

  • 1. Prescription drug monitoring programs.
    Harrison B
    NCSL Legisbrief; 2006 Jan; 14(4):1-2. PubMed ID: 16465702
    [No Abstract]   [Full Text] [Related]  

  • 2. Summary and conclusions of a review of prescription drug diversion control methods.
    Horgan C; Prottas J; Tompkins C; Wastila L; Bowden M
    NIDA Res Monogr; 1993; 131():206-23. PubMed ID: 8413532
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple copy prescription programs and alternative monitoring programs: cost issues.
    Collins TM
    N Y State J Med; 1991 Nov; 91(11 Suppl):28S-31S. PubMed ID: 1771056
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain.
    Fishman SM; Papazian JS; Gonzalez S; Riches PS; Gilson A
    Pain Med; 2004 Sep; 5(3):309-24. PubMed ID: 15367312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programs for monitoring inappropriate prescribing of controlled drugs: evaluation and recommendations.
    Collins TM; Zimmerman DR
    Am J Hosp Pharm; 1992 Jul; 49(7):1765-8. PubMed ID: 1621738
    [No Abstract]   [Full Text] [Related]  

  • 6. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.
    Weintraub M; Singh S; Byrne L; Maharaj K; Guttmacher L
    NIDA Res Monogr; 1993; 131():279-93. PubMed ID: 8105386
    [No Abstract]   [Full Text] [Related]  

  • 7. Triplicate prescription: issues and answers. Introduction.
    Farnsworth PB
    N Y State J Med; 1991 Nov; 91(11 Suppl):1S-4S. PubMed ID: 1771052
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of prescription drug control systems on medical practice and patient care: a summary of the NIDA technical review.
    NIDA Res Monogr; 1993; 131():1-17. PubMed ID: 8413519
    [No Abstract]   [Full Text] [Related]  

  • 9. An American Medical Association perspective on preventing prescription drug diversion.
    Ambre JJ
    NIDA Res Monogr; 1993; 131():224-7. PubMed ID: 8413533
    [No Abstract]   [Full Text] [Related]  

  • 10. Dear DEA.
    Heit HA; Covington E; Good PM
    Pain Med; 2004 Sep; 5(3):303-8. PubMed ID: 15367311
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug diverting patients & prescription monitoring--both sides of the debate.
    Freeman J
    Iowa Med; 2004; 94(5):10-1. PubMed ID: 15560649
    [No Abstract]   [Full Text] [Related]  

  • 12. Prescription database: a new tool in drug fight.
    Gadea J
    Conn Med; 2010 Mar; 74(3):169-70. PubMed ID: 20391826
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescription Drug Monitoring Programs - Friend or Folly in Addressing the Opioid-Overdose Crisis?
    Haffajee RL
    N Engl J Med; 2019 Aug; 381(8):699-701. PubMed ID: 31433916
    [No Abstract]   [Full Text] [Related]  

  • 14. Dispensing, prescribing and administering drugs: what you need to know.
    MDA Special Committee on Care and Well Being
    J Mich Dent Assoc; 2010 Mar; 92(3):46-50. PubMed ID: 20391816
    [No Abstract]   [Full Text] [Related]  

  • 15. Dentistry: controlled substances and enforcement.
    Hankins HH
    Ark Dent J; 1979 Jun; 50(2):12-5. PubMed ID: 119520
    [No Abstract]   [Full Text] [Related]  

  • 16. The DEA proposes schedule II substance rule.
    Buchanan BL
    WMJ; 2007 Jul; 106(4):230. PubMed ID: 17844715
    [No Abstract]   [Full Text] [Related]  

  • 17. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Feb; 75(20):4973-82. PubMed ID: 20352663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drug regulations and diversion control systems on legitimate narcolepsy patients.
    Piscopo JA
    NIDA Res Monogr; 1993; 131():249-59. PubMed ID: 8105384
    [No Abstract]   [Full Text] [Related]  

  • 19. Diversion investigation units--methods, utilities, and limitations.
    Bulla RK
    NIDA Res Monogr; 1993; 131():145-50. PubMed ID: 8413525
    [No Abstract]   [Full Text] [Related]  

  • 20. Electronic prescriptions for controlled substances.
    Optometry; 2010 Jul; 81(7):367-72. PubMed ID: 20665957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.